mTOR inhibition in T-cell lymphoma: a path(way) forward. Article uri icon

Overview

abstract

  • In this issue of Blood, Witzig et al report on the promising in vitro and in vivo activity of everolimus in T-cell lymphoma (TCL) and pave the way for future combination studies.

publication date

  • July 16, 2015

Research

keywords

  • Immunosuppressive Agents
  • Lymphoma, T-Cell
  • Multiprotein Complexes
  • Neoplasm Recurrence, Local
  • Sirolimus
  • TOR Serine-Threonine Kinases

Identity

Scopus Document Identifier

  • 84937797977

Digital Object Identifier (DOI)

  • 10.1182/blood-2015-05-644724

PubMed ID

  • 26185115

Additional Document Info

volume

  • 126

issue

  • 3